Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients
Authors:
- Nermin UncuNUNermin Uncu
- Banu Acar ÇelikelBÇBanu Acar Çelikel
- Aysel TaktakATAysel Taktak
- Gökçe GürGGGökçe Gür
- Nilgun CakarNCNilgun Cakar
- 22 December 2014
- journal article
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 25 (4) , 621-624
Abstract
The aim of this report was to evaluate and discuss treatment of pediatric familial Mediterranean fever (FMF) patients with anti-interleukin1 (IL-1) agents. Refractory or colchicine unresponsive FMF was described as severe and frequent attacks and/or having high acute phase reactance levels despite having a maximum dose of colchicine (2 mg/day). Disease course, adverse effects, duration of follow-up, treatment protocols, responses to the therapies were discussed. Eight patients (6 male, 2 female) having refractory FMF were identified. Mediterranean fever (MEFV) gene analyses revealed homozygous M694V mutations in six patients and heterozygote M694V mutations in one patient and no mutation in one patient. They were all treated with anakinra and/or canakinumab. The use of anti-IL-1 drugs was beneficial to all patients. None of them had any severe adverse effects due to the therapy. Anakinra and canakinumab were effective in patient refractory to colchicine treatment as shown both in our series and in the literature. Therefore, controlled trials are needed to evaluate the safety and long-term efficacy of IL-1 targeting agents in colchicine resistant patients.Keywords
This publication has 15 references indexed in Scilit:
- Treating inflammation by blocking interleukin-1 in humansSeminars in Immunology, 2013
- Incomplete response to colchicine in M694V homozygote FMF patientsAutoimmunity Reviews, 2012
- Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromesClinical and Experimental Immunology, 2012
- Interleukin-1 Targeting Drugs in Familial Mediterranean Fever: A Case Series and a Review of the LiteratureSeminars in Arthritis and Rheumatism, 2011
- Application of the new pediatric criteria and Tel Hashomer criteria in heterozygous patients with clinical features of FMFEuropean Journal of Pediatrics, 2011
- Interleukin-1β and the Autoinflammatory DiseasesNew England Journal of Medicine, 2009
- The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean feverEuropean Journal of Pediatrics, 2007
- Colchicine Use in Children and Adolescents With Familial Mediterranean Fever: Literature Review and Consensus StatementPediatrics, 2007
- Colchicine nonresponsiveness in familial mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterizationSeminars in Arthritis and Rheumatism, 2004
- Clinical differences between North African and Iraqi Jews with familial Mediterranean feverAmerican Journal of Medical Genetics, 1998